Back to top
more

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$1.62 USD

1.62
5,876,279

-0.08 (-4.71%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $1.63 +0.01 (0.62%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.

Varian (VAR) Earnings and Revenues Surpass Estimates in Q2

by Zacks Equity Research

Varian (VAR) continued to gain from core Oncology Systems segment in Q2.

Luminex (LMNX) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.

CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.

PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.

Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings gain from strong performance at MedSurg and Neurotechnology and Spine units.

Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.

ABIOMED (ABMD) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter earnings benefit from solid segmental performance and growth across all geographies.

Will Pacific Biosciences of California (PACB) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.

Masimo (MASI) Q1 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Masimo (MASI) sees solid growth in key Product segment in Q1.

Here's Why You Should Retain Inogen (INGN) Stock for Now

by Zacks Equity Research

Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.

Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec

by Zacks Equity Research

Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.

Why Is Pacific Biosciences (PACB) Down 18.1% Since Last Earnings Report?

by Zacks Equity Research

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Can PennyMac (PFSI) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

PennyMac (PFSI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Ensign Group (ENSG) Stock

by Zacks Equity Research

Ensign Group (ENSG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4

by Zacks Equity Research

Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.

Pacific Biosciences of California (PACB) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 100.00% and 9.79%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Pacific Biosciences Stock Now

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Pacific Biosciences (PACB) Up 2.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Pacific Biosciences Stock

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Options Traders Expect Huge Moves in Pacific Biosciences (PACB) Stock

by Zacks Equity Research

Investors need to pay close attention to Pacific Biosciences (PACB) stock based on the movements in the options market lately.